Thomas Clozel
CEO
Owkin
SwitzerlandThomas Clozel is a visionary oncologist and entrepreneur, and a pioneer of agentic AI in life sciences. He is the co-founder and CEO of Owkin, where he leads the development of Owkin K, the world’s first biology-native AI scientist powered by a proprietary biology LLM and a multimodal data moat. Under his leadership, the company is accelerating drug discovery, enabling AI-driven therapies, and laying the foundations for Biological Artificial Superintelligence. Owkin is redefining how medical decisions and therapies are developed and delivered. Thomas is based in Geneva.
Main
Main
Europe’s Billion-Euro Problem
Europe is producing more exciting AI startups than ever, but very few make it to becoming billion-euro companies. The gap isn’t at the idea stage, it’s what happens after the seed round. Why do some startups manage to raise growth capital, scale internationally, and break out, while others stall when things get serious? With early-stage talent at an all-time high, what’s standing in the way of Europe’s next generation of billion-euro AI companies?
Best for:
Startup FounderCapital Provider
AGENDA AT A GLANCE
READY TO BE PART OF IT?
Don't miss out on the premier AI event of the year! Get your tickets now and be part of the future of technology!